Healthcare Experience


Our Healthcare experience includes 846 clients, with 34 partnered Metabolic Disorders brands and 816 USAN/INN names. Below is our extensive portfolio, feel free to filter by clients, brands, category or USAN/INN Names.   ||  Click Here for Consumer/B2B Experience



CLIENTS BRANDS CATEGORY
Abeona rebisufligene etisparvovec Metabolic Disorders
AEGERION PHARMACEUTICALS MYALEPTA Metabolic Disorders
AGIOS mitapivat Metabolic Disorders
ALBIREO odevixibat Metabolic Disorders
ALEXION PHARMACEUTICALS KANUMA * Metabolic Disorders
ASCENDIS PHARMA lonapegsomatropin Metabolic Disorders
BASF AGRICULTURE icosabutate Metabolic Disorders
BIOMARIN pegvaliase Metabolic Disorders
BIOMARIN reveglucosidase alfa Metabolic Disorders
BIOMARIN tralesinidase alfa Metabolic Disorders
CATABASIS PHARMACEUTICALS edasalonexent Metabolic Disorders
CATABASIS PHARMACEUTICALS nicodicosapent Metabolic Disorders
CORCEPT THERAPEUTICS miricorilant Metabolic Disorders
CORCEPT THERAPEUTICS RELACORILANT Metabolic Disorders
Ferring PHARMACEUTICALS apraglutide Metabolic Disorders
Genexine eftansomatropin alfa Metabolic Disorders
Gilead cilofexor Metabolic Disorders
Gilead firsocostat Metabolic Disorders
GlaxoSmithKline linerixibat Metabolic Disorders
LYSOGENE olenasufligene relduparvovec Metabolic Disorders
MADRIGAL resmetirom Metabolic Disorders
Millendo livoletide Metabolic Disorders
NGM BIOPHARMACEUTICALS aldafermin Metabolic Disorders
NOVO NORDISK somapacitan Metabolic Disorders
REMD volagidemab Metabolic Disorders
REMD BIOTHERAPEUTICS volagidemab Metabolic Disorders
SANGAMO THERAPEUTICS devafidugene civaparvovec Metabolic Disorders
SANGAMO THERAPEUTICS tefidsogene civaparvovec Metabolic Disorders
SHIRE PHARMACEUTICALS maralixibat chloride Metabolic Disorders
SHIRE PHARMACEUTICALS valanafusp alfa Metabolic Disorders
TEVA PHARMACEUTICAL INDUSTRIES albusomatropin Metabolic Disorders
ULTRAGENYX PHARMACEUTICAL triheptanoin Metabolic Disorders
UNIQURE BIOPHARMA GLYBERA Metabolic Disorders
VALERION THERAPEUTICS clervonafusp alfa Metabolic Disorders
VERSARTIS somavaratan Metabolic Disorders


* Denotes a comprehensive report of the safety regulatory research prepared by BI/DSI for submission of this name candidate to FDA, EMA, Health Canada, JMHLW, ANVISA, ROSZDRAVNADZOR, CDSCO, CFDA, KOREA MFDS, and/or other Regulatory Agencies.

Back to top